Myriad Genetics adds 15 clinically actionable genes to MyRisk test

Myriad Genetics (MYGN) announced MyRisk Hereditary Cancer Test-the gold standard in germline testing-has been expanded to include genes referenced in NCCN Clinical Practice Guidelines in Oncology and guidelines from American Society of Clinical Oncology, ASCO. These genes are strongly associated with cancer risk and may have clear clinical actionability, supporting the goal that each addition to the panel provides meaningful insights for patient care. The updated MyRisk panel now includes 63 carefully selected genes across more than 11 cancer types, reflecting Myriad’s commitment to meeting evolving clinical needs.